Inhibin subunit alpha (INHA) mRNA (INHA mRNA)

Inhibin subunit alpha (INHA) mRNA is the transcript responsible for the synthesis of the alpha subunit of the inhibin protein, a critical regulator within the transforming growth factor-beta (TGF-beta) superfamily [1]. The alpha subunit dimerizes with various beta subunits to form Inhibin A or Inhibin B, which primarily function to suppress the secretion of follicle-stimulating hormone (FSH) from the pituitary gland via a negative feedback loop [1, 2]. In clinical oncology, INHA mRNA and its protein products are significant biomarkers for ovarian granulosa cell tumors and certain mucinous carcinomas, where elevated expression levels are often observed [3]. Therapeutic targeting of INHA mRNA is an active area of preclinical research, utilizing RNA interference (RNAi) and antisense oligonucleotides (ASOs) to downregulate expression for the purpose of modulating reproductive hormones or inhibiting tumor growth [4]. By silencing the INHA transcript, researchers aim to disrupt the inhibin-activin balance, which has implications for treating infertility, polycystic ovary syndrome (PCOS), and hormone-dependent malignancies [2, 4]. However, therapeutic intervention at the mRNA level must carefully manage the risk of systemic endocrine disruption and potential impacts on the broader TGF-beta signaling network [1, 3].

Other names

Inhibin alpha subunit mRNAINHA transcriptInhibin alpha-chain mRNAInhibin alpha mRNA

Targeted degradation of INHA mRNA via the RNA-induced silencing complex (RISC) or RNase H-mediated cleavage, leading to reduced inhibin alpha subunit protein synthesis.